Decrease of Serum Angiotensin Converting Enzyme Activity after Discontinuation of Captopril Treatment (original) (raw)
Effect of Time and Dose on Angiotensin Converting Enzyme during Captopril Treatment in the Rat
T. Forslund
Acta Pharmacologica et Toxicologica, 1983
View PDFchevron_right
Induction of angiotensin I-converting enzyme in rat lung with captopril (SQ 14225)
T. Forslund
European Journal of Pharmacology, 1980
View PDFchevron_right
Dissociation of the effect of captopril on blood pressure and angiotensin converting enzyme in serum and lungs of spontaneously hypertensive rats
T. Forslund
Acta pharmacologica et toxicologica, 1981
View PDFchevron_right
Effect of a short-term captopril treatment on serum and tissue angiotensin I-converting enzyme activity from four mammalian species. Differences using diamide in the in vitro assay
Noel Cruz
Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology, 1993
View PDFchevron_right
Induction of angiotensin-converting enzyme with the ACE inhibitory compound MK-421 in rat lung
T. Forslund
European Journal of Pharmacology, 1982
View PDFchevron_right
Induction of angiotensin I-converting enzyme in rat lung with captopril: The effect of adrenalectomy
T. Forslund
The American Journal of Cardiology, 1982
View PDFchevron_right
Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats
Dirk K F Meijer
British Journal of Pharmacology, 2002
View PDFchevron_right
Inhibition of tissue angiotensin converting enzyme. Quantitation by autoradiography
Frederick Mendelsohn
Hypertension, 1988
View PDFchevron_right
INHIBITION OF ANGIOTENSIN-CONVERTING ENZYME BY CAPTOPRIL: A NOVEL APPROACH TO REDUCE ISCHEMIA-REPERFUSION INJURY AFTER LUNG TRANSPLANTATION
Alexandra MacLean
2000
View PDFchevron_right
Contribution of angiotensin II in hepatic ischemia /reperfusion induced lung injury: Acute versus chronic usage of captopril
Marwa Mehesen, asmaa shams eldeen
View PDFchevron_right
Acute and Chronic Effects of Angiotensin-Converting Enzyme Inhibitors on Tissue Angiotensin-Converting Enzyme
Frederick Mendelsohn
Clinical and Experimental Pharmacology and Physiology, 1992
View PDFchevron_right
Plasma-converting enzyme activity does not reflect effectiveness of oral treatment with captopril
Thomas Unger
European Journal of Pharmacology, 1981
View PDFchevron_right
An Angiotensin-Converting Enzyme (ACE) Inhibitor in Human Serum
Sonal Singh
Chest, 1986
View PDFchevron_right
Renal and Metabolic Clearance of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (AcSDKP) During Angiotensin-Converting Enzyme Inhibition in Humans
Joanna Bakala
Hypertension, 1999
View PDFchevron_right
Acute and Chronic Effects of Perindopril on Tissue Angiotensin Converting Enzyme Activity
Frederick Mendelsohn
American Journal of Hypertension, 1991
View PDFchevron_right
Renal and pulmonary effects of angiotensin converting enzyme inhibition in chronic hypoxic lung disease
John Fleming
Thorax, 1989
View PDFchevron_right
Targeting of Captopril to the Kidney Reduces Renal Angiotensin-Converting Enzyme Activity without Affecting Systemic Blood Pressure
Robbert Kok
Journal of Pharmacology and Experimental Therapeutics, 2002
View PDFchevron_right
The acute haemodynamic effects of captopril in dogs with heart failure
Paul Pion
Journal of Veterinary Pharmacology and Therapeutics, 1993
View PDFchevron_right
Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS Investigators
Hendrik Buikema
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy, 2000
View PDFchevron_right
Lack of correlation between the acute haemodynamic response to intravenous captopril and plasma concentrations of angiotensin II in patients with chronic cardiac failure
Marius Rademaker
European Journal of Clinical Pharmacology, 1992
View PDFchevron_right
Dissociation between in vivo and in vitro measurements of converting enzyme activity after chronic oral treatment with captopril in rats
Thomas Unger
The American Journal of Cardiology, 1982
View PDFchevron_right
Evaluation of the ability of the angiotensin-converting enzyme inhibitor captopril to scavenge reactive oxygen species
Rubens Cecchini
1991
View PDFchevron_right
Angiotensin Converting Enzyme in the Rat Heart: Studies of Its Inhibition in Vitro and Ex Vivo
Frederick Mendelsohn
Clinical and Experimental Pharmacology and Physiology, 1989
View PDFchevron_right
Tissue distribution of captopril, reducible captopril conjugates and S-methylcaptopril in the rat
Olaf Drummer
Biochemical Pharmacology, 1983
View PDFchevron_right
Changes in angiotensin-converting enzyme activity in lungs damaged by the pyrrolizidine alkaloid monocrotaline
RJ Huxtable
Thorax, 1983
View PDFchevron_right
Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: Interaction with low dose acetylsalicylic acid
Dimitrios Tsikas
British Journal of Clinical Pharmacology, 2003
View PDFchevron_right
Enflurane, halothane and isoflurane do not inhibit angiotensin converting enzyme activity
Barbara Brandom
Canadian Anaesthetists’ Society Journal, 1985
View PDFchevron_right
Captopril kinetics in chronic congestive heart failure
Gary Schaer
Clinical Pharmacology and Therapeutics, 1982
View PDFchevron_right
A continuous fluorescent assay for the determination of plasma and tissue angiotensin I-converting enzyme activity
Luiz Juliano
Brazilian Journal of Medical and Biological Research, 2005
View PDFchevron_right